AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
troglitazone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| peroxisome proliferator activating receptor-gamma (PPAR-gamma) agonists, thiazolidinedione derivatives | 2767 | 97322-87-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.40 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 22.65 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Hosey CM, Chan R, Benet LZ |
| BA (Bioavailability) | 45 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| S (Water solubility) | 0.00 mg/mL | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AXL,BRAF,BTK,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,MAPK7,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PRKDC,TGFBR1 | 21 | |||
| kinase-selectivity-class | BRAF,EIF2AK3,GRK2,MAP2K6,TEK | 5 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 29, 1997 | FDA | PFIZER PHARMS |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A10BG01 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Thiazolidinediones |
| MeSH PA | D007004 | Hypoglycemic Agents |
| CHEBI has role | CHEBI:22586 | antioxidant |
| CHEBI has role | CHEBI:35526 | hypoglycemic agent |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:35620 | vasodilator agent |
| CHEBI has role | CHEBI:35623 | anticonvulsant |
| CHEBI has role | CHEBI:50249 | anticoagulant |
| CHEBI has role | CHEBI:50427 | platelet aggregation inhibitor |
| CHEBI has role | CHEBI:83157 | EC 6.2.1.3 (long-chain-fatty-acid—CoA ligase) inhibitor |
| CHEBI has role | CHEBI:173084 | ferroptosis inhibitor |
Related Drugs by ATC class:
A10BG Thiazolidinediones 3 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Diabetes mellitus type 2 | indication | 44054006 | DOID:9352 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 6.33 | acidic |
| pKa2 | 12.07 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Peroxisome proliferator-activated receptor gamma | Nuclear hormone receptor | AGONIST | EC50 | 6.27 | WOMBAT-PK | CHEMBL | |||
| 5-hydroxytryptamine receptor 2B | GPCR | Ki | 6.08 | DRUG MATRIX | |||||
| Adenosine receptor A3 | GPCR | Ki | 5.53 | DRUG MATRIX | |||||
| Carbonic anhydrase 2 | Enzyme | IC50 | 6.01 | DRUG MATRIX | |||||
| Bile salt export pump | Transporter | IC50 | 5.57 | CHEMBL | |||||
| Cytochrome P450 2C9 | Enzyme | IC50 | 5.40 | DRUG MATRIX | |||||
| Amine oxidase [flavin-containing] B | Enzyme | Ki | 5.02 | CHEMBL | |||||
| Amine oxidase [flavin-containing] A | Enzyme | Ki | 4.98 | CHEMBL | |||||
| Aldose reductase | Enzyme | WOMBAT-PK | |||||||
| Tyrosine-protein phosphatase non-receptor type 1 | Enzyme | IC50 | 4.26 | CHEMBL | |||||
| Glycogen [starch] synthase, liver | Enzyme | WOMBAT-PK | |||||||
| Thromboxane-A synthase | Enzyme | IC50 | 5.53 | DRUG MATRIX | |||||
| Mitogen-activated protein kinase 1 | Kinase | IC50 | 5.91 | DRUG MATRIX | |||||
| UDP-glucuronosyltransferase 1-6 | Enzyme | Ki | 4.70 | CHEMBL | |||||
| Cytochrome P450 3A4 | Enzyme | Km | 3.21 | WOMBAT-PK | |||||
| Forkhead box protein M1 | Transcription factor | Ki | 7.28 | CHEMBL | |||||
| Aldose reductase | Enzyme | IC50 | 5.69 | DRUG MATRIX | |||||
| Amine oxidase [flavin-containing] B | Enzyme | Ki | 4.96 | CHEMBL | |||||
| Amine oxidase [flavin-containing] A | Enzyme | Ki | 5.32 | CHEMBL | |||||
| Indoleamine 2,3-dioxygenase 2 | Enzyme | IC50 | 5.35 | CHEMBL | |||||
| Indoleamine 2,3-dioxygenase 1 | Enzyme | IC50 | 4.21 | CHEMBL | |||||
| Bile salt export pump | Transporter | IC50 | 4.97 | CHEMBL | |||||
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Enzyme | IC50 | 4.70 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4020997 | VUID |
| N0000148466 | NUI |
| D00395 | KEGG_DRUG |
| 4020997 | VANDF |
| C0245514 | UMLSCUI |
| CHEBI:9753 | CHEBI |
| TDZ | PDB_CHEM_ID |
| CHEMBL408 | ChEMBL_ID |
| D000077288 | MESH_DESCRIPTOR_UI |
| DB00197 | DRUGBANK_ID |
| 2693 | IUPHAR_LIGAND_ID |
| 6851 | INN_ID |
| I66ZZ0ZN0E | UNII |
| 5591 | PUBCHEM_CID |
| 203715 | RXNORM |
| 5640 | MMSL |
| 9149 | MMSL |
| d04122 | MMSL |
| 006355 | NDDF |
| 109085002 | SNOMEDCT_US |
| 386967007 | SNOMEDCT_US |
| I66ZZ0ZN0E | INXIGHT DRUGS |
Pharmaceutical products:
None